Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.

NCT Number	NCT07408440
Lead Sponsor	The University of Texas Health Science Center, Houston
Conditions	Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Enrollment	150 participants
Start Date	2026-04-01
Primary Completion	2028-03-30 (estimated)
Study Completion	2028-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-17